Personalis and Collaborators to Highlight Ultrasensitive ctDNA Data and New Therapy Resistance Tracking Capabilities at AACR 2026Business Wire • 04/13/26
Personalis Appoints Dr. Richard Chen as President to Further Accelerate MRD AdoptionBusiness Wire • 03/17/26
Personalis Announces New Publication Advancing Neoadjuvant Treatment Monitoring in Breast Cancer with NeXT Personal®Business Wire • 03/12/26
Personalis Reports Fourth Quarter and Full Year 2025 Results and Recent HighlightsBusiness Wire • 02/26/26
Personalis Receives Medicare Coverage for NeXT Personal® in Lung Cancer SurveillanceBusiness Wire • 02/10/26
Personalis Announces New Publication Expanding Evidence for Ultrasensitive ctDNA Monitoring of Cancer Immunotherapy Response Across Solid TumorsBusiness Wire • 02/02/26
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceBusiness Wire • 01/28/26
Personalis Pioneers Advancement in MRD Testing with the Launch of its Real-Time Variant Tracker™Business Wire • 01/12/26
Personalis Reports Select Preliminary Fourth Quarter and Full Year 2025 Results and Recent HighlightsBusiness Wire • 01/08/26
Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid TumorsBusiness Wire • 12/17/25
New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung CancerBusiness Wire • 12/11/25
Personalis to Participate in the Piper Sandler 37th Annual Healthcare ConferenceBusiness Wire • 11/18/25
Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast CancerBusiness Wire • 11/10/25
Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD TestingBusiness Wire • 10/16/25